
<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <title>Bokeh Plot</title>
        
<link rel="stylesheet" href="https://cdn.pydata.org/bokeh/release/bokeh-0.12.3.min.css" type="text/css" />
<link rel="stylesheet" href="https://cdn.pydata.org/bokeh/release/bokeh-widgets-0.12.3.min.css" type="text/css" />
        
<script type="text/javascript" src="https://cdn.pydata.org/bokeh/release/bokeh-0.12.3.min.js"></script>
<script type="text/javascript" src="https://cdn.pydata.org/bokeh/release/bokeh-widgets-0.12.3.min.js"></script>
<script type="text/javascript">
    Bokeh.set_log_level("info");
</script>
        <style>
          html {
            width: 100%;
            height: 100%;
          }
          body {
            width: 90%;
            height: 100%;
            margin: auto;
          }
        </style>
    </head>
    <body>
        
        <div class="bk-root">
            <div class="plotdiv" id="f040c4f1-247f-4c3e-b0c0-eaacde681cf6"></div>
        </div>
        
        <script type="text/javascript">
            Bokeh.$(function() {
            Bokeh.safely(function() {
                var docs_json = {"160801ec-0357-4b8b-9c1c-de4999d90814":{"roots":{"references":[{"attributes":{"columns":[{"id":"bcf2e0e2-a4f9-4bb4-ac97-c64feca9091b","type":"TableColumn"}],"source":{"id":"c23780cd-1fc4-403a-9930-bf03aa428cc1","type":"ColumnDataSource"},"width":1024},"id":"77f61fec-cd82-4d4a-98fe-5b2c3b4ee5eb","type":"DataTable"},{"attributes":{"dilate":true,"fill_color":{"value":"#3182bd"},"height":{"units":"data","value":0.95},"line_color":{"value":"#3182bd"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"c0be3707-b3a4-4dc0-9f1a-5eb3fa9870a8","type":"Rect"},{"attributes":{"data_source":{"id":"3c43bcf5-2bac-4072-b7d6-a5f81a9089d5","type":"ColumnDataSource"},"glyph":{"id":"a4f3e6c8-cd88-4936-98d0-2ecd7d0b8d5f","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"e2f5d78f-c34c-4f9b-9437-04535c1ea941","type":"GlyphRenderer"},{"attributes":{"data_source":{"id":"528480e9-9b7b-4746-a1e3-cf85bc04b4f4","type":"ColumnDataSource"},"glyph":{"id":"4472018b-b250-4a8b-87b0-f90e26b1dc00","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"428917bd-c1d2-46b8-8edd-1bfa807ee461","type":"GlyphRenderer"},{"attributes":{"axis_label":"phenotype","formatter":{"id":"6982d493-7f65-44a4-94e8-0977f5c4e695","type":"CategoricalTickFormatter"},"major_label_orientation":0.7853981633974483,"plot":{"id":"ed96736f-790c-437b-be7f-9bc9e061a02d","subtype":"Chart","type":"Plot"},"ticker":{"id":"7ae607e2-f81d-4771-b5ba-667b12dcb051","type":"CategoricalTicker"}},"id":"c022db35-1c4c-481a-894f-0fea80160e45","type":"CategoricalAxis"},{"attributes":{"plot":null,"text":"G2P Associations for KIT"},"id":"86df1ed1-dc71-4934-b0b6-b1c4f08c1fdb","type":"Title"},{"attributes":{"children":[{"id":"ed96736f-790c-437b-be7f-9bc9e061a02d","subtype":"Chart","type":"Plot"},{"id":"fdad9a6f-b3c9-446b-8149-bb2e5eab8cfd","type":"WidgetBox"}]},"id":"5408e6a3-f8ec-401d-9854-f663f63c0b81","type":"Column"},{"attributes":{},"id":"2d101e3c-f9af-42c2-975e-e40d54df6a05","type":"ToolEvents"},{"attributes":{"dilate":true,"fill_color":{"value":"#9ecae1"},"height":{"units":"data","value":0.95},"line_color":{"value":"#9ecae1"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"108ca698-e116-422a-9f5f-609d48defae3","type":"Rect"},{"attributes":{},"id":"aeb07670-5984-4ed5-a2d4-4c253d3118c6","type":"CategoricalTickFormatter"},{"attributes":{"axis_label":"phenotype","formatter":{"id":"938484eb-2a62-451d-869b-deaf08e5352f","type":"CategoricalTickFormatter"},"major_label_orientation":0.7853981633974483,"plot":{"id":"e4926516-61dc-46a0-9028-408b0af31f76","subtype":"Chart","type":"Plot"},"ticker":{"id":"6bac9814-85c3-47f3-b208-b94d36fc9a34","type":"CategoricalTicker"}},"id":"aad59b6a-5efd-4831-848f-9bc237a5d0a3","type":"CategoricalAxis"},{"attributes":{"data_source":{"id":"d31551d5-8b44-4f89-bcd9-3f8441f6f4c8","type":"ColumnDataSource"},"glyph":{"id":"28f579e8-c9de-4c7e-a06d-a3c609ee9123","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"9470cc1a-8233-48f3-8d53-87c41126dd7c","type":"GlyphRenderer"},{"attributes":{"dilate":true,"fill_color":{"value":"#6baed6"},"height":{"units":"data","value":0.95},"line_color":{"value":"#6baed6"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"9c6efd8f-e7de-4c3b-8688-a1efa4c0060b","type":"Rect"},{"attributes":{"callback":null,"plot":{"id":"e4926516-61dc-46a0-9028-408b0af31f76","subtype":"Chart","type":"Plot"},"tooltips":[["associations","@values"]]},"id":"8e780433-2985-460c-8713-749ff8e085fc","type":"HoverTool"},{"attributes":{"data_source":{"id":"5c592772-76e2-4f36-8142-700dfb4ef188","type":"ColumnDataSource"},"glyph":{"id":"108ca698-e116-422a-9f5f-609d48defae3","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"c7b195b4-a065-433d-9c7a-a9628ba9264d","type":"GlyphRenderer"},{"attributes":{"axis_label":"phenotype","formatter":{"id":"aeb07670-5984-4ed5-a2d4-4c253d3118c6","type":"CategoricalTickFormatter"},"major_label_orientation":0.7853981633974483,"plot":{"id":"b304ec13-99ef-4b12-8a2f-c6a6bee9d509","subtype":"Chart","type":"Plot"},"ticker":{"id":"15ca3379-54f0-4ca3-9cd6-ee55a3396321","type":"CategoricalTicker"}},"id":"5571b6fa-493d-4faa-bf5b-d26d93762471","type":"CategoricalAxis"},{"attributes":{"dilate":true,"fill_color":{"value":"#08519c"},"height":{"units":"data","value":0.95},"line_color":{"value":"#08519c"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"ae89abe6-5cb5-4013-a55a-f654895f24ea","type":"Rect"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]"],"chart_index":[{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"}],"values":[1,1,2,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1],"x":["KIT exon 8 p.416-422 indel","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT  D816V missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT  wild type no mutation","KIT V560del deletion mutation","KIT  wild type no mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT D820Y missense mutation","KIT exon 17 p.788-828 any mutation","KIT amplification copy number gain","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT D820E missense mutation","KIT del577-578_579 deletion mutation","KIT amplification copy number gain"],"y":["ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","Mastocytosis with response to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","GIST with response to therapy","Melanoma, NOS with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with response to therapy","Thymic carcinoma with response to therapy","GIST with sensitivity to therapy","GIST with sensitivity to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with response to therapy","Melanoma, NOS with no response to therapy"]}},"id":"a6d987ef-c5f2-4bc3-9a95-8cf409ac0c74","type":"ColumnDataSource"},{"attributes":{"dilate":true,"fill_color":{"value":"#9ecae1"},"height":{"units":"data","value":0.95},"line_color":{"value":"#9ecae1"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"afc9022d-044f-4d18-853e-418ee304abc5","type":"Rect"},{"attributes":{"plot":null,"text":"G2P Associations for KIT"},"id":"b306a010-604b-42ab-800c-db7a97187b40","type":"Title"},{"attributes":{"children":[{"id":"77f61fec-cd82-4d4a-98fe-5b2c3b4ee5eb","type":"DataTable"}],"height":400,"width":1024},"id":"5f8c11af-ddb5-4858-a77b-ea729b940d8a","type":"WidgetBox"},{"attributes":{"dilate":true,"fill_color":{"value":"#3182bd"},"height":{"units":"data","value":0.95},"line_color":{"value":"#3182bd"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"28f579e8-c9de-4c7e-a06d-a3c609ee9123","type":"Rect"},{"attributes":{"children":[{"id":"b304ec13-99ef-4b12-8a2f-c6a6bee9d509","subtype":"Chart","type":"Plot"},{"id":"8bf9dd7b-50a9-40dc-b1b1-5bc5b4b81cf2","type":"WidgetBox"}]},"id":"28325ef4-0d60-4aa6-b910-4960dc5a3d1c","type":"Column"},{"attributes":{"below":[{"id":"4b23ef13-f679-4cea-856c-2f2414f4f778","type":"CategoricalAxis"}],"left":[{"id":"c022db35-1c4c-481a-894f-0fea80160e45","type":"CategoricalAxis"}],"renderers":[{"id":"462c3e89-6cb6-4471-93dc-4a4206738801","type":"GlyphRenderer"},{"id":"d272a6ed-79f6-4ba2-85dc-3d6b15cad1e6","type":"GlyphRenderer"},{"id":"597a4e97-4761-474a-ab93-4e943d435eff","type":"GlyphRenderer"},{"id":"428917bd-c1d2-46b8-8edd-1bfa807ee461","type":"GlyphRenderer"},{"id":"4b23ef13-f679-4cea-856c-2f2414f4f778","type":"CategoricalAxis"},{"id":"c022db35-1c4c-481a-894f-0fea80160e45","type":"CategoricalAxis"}],"title":{"id":"2e2ba6e0-7810-40fc-b8a5-1b380315745b","type":"Title"},"tool_events":{"id":"aa31737d-002c-47d7-8794-b77075f02aca","type":"ToolEvents"},"toolbar":{"id":"a0ad3f37-459d-46f1-bc8a-91cea310e5e4","type":"Toolbar"},"toolbar_location":"above","width":1024,"x_mapper_type":"auto","x_range":{"id":"e6f0b92c-e393-44f1-ac62-8f9de7e2ee3d","type":"FactorRange"},"y_mapper_type":"auto","y_range":{"id":"9264f517-2bba-4919-9aac-204859930a00","type":"FactorRange"}},"id":"ed96736f-790c-437b-be7f-9bc9e061a02d","subtype":"Chart","type":"Plot"},{"attributes":{"callback":null,"plot":{"id":"b304ec13-99ef-4b12-8a2f-c6a6bee9d509","subtype":"Chart","type":"Plot"},"tooltips":[["associations","@values"]]},"id":"58b9699e-4f4b-47a7-9689-380bf61ea448","type":"HoverTool"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(7, 8.5]"],"chart_index":[{"association_count_Sum":"(7, 8.5]"}],"values":[8],"x":["KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation"],"y":["GIST with resistance to therapy"]}},"id":"4ffb8a64-8faf-4270-ae11-655871819d22","type":"ColumnDataSource"},{"attributes":{"data_source":{"id":"30b0c06a-7cd2-41d0-963d-e99e70072573","type":"ColumnDataSource"},"glyph":{"id":"95af79db-d3d9-4b4f-80ee-34b4b561ba3e","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"89038575-5642-46c2-8242-478afd78f9fb","type":"GlyphRenderer"},{"attributes":{"data_source":{"id":"a6d987ef-c5f2-4bc3-9a95-8cf409ac0c74","type":"ColumnDataSource"},"glyph":{"id":"afc9022d-044f-4d18-853e-418ee304abc5","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"95c38428-0815-479a-9d2d-1e50e3c4f8af","type":"GlyphRenderer"},{"attributes":{"callback":null,"factors":["GIST with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","Melanoma, NOS with response to therapy","Mastocytosis with response to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","Melanoma, NOS with resistance to therapy","GIST with sensitivity to therapy","Melanoma, NOS with no response to therapy"]},"id":"9264f517-2bba-4919-9aac-204859930a00","type":"FactorRange"},{"attributes":{},"id":"9ab2a56c-7632-4de2-84ef-509ce8ea9c85","type":"StringFormatter"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(2.5, 4]"],"chart_index":[{"association_count_Sum":"(2.5, 4]"}],"values":[3],"x":["KIT exon 11 p.550-592 any mutation"],"y":["GIST with response to therapy"]}},"id":"92c117b0-9c1f-4e8f-83d3-c09279917cf1","type":"ColumnDataSource"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(7, 8.5]"],"chart_index":[{"association_count_Sum":"(7, 8.5]"}],"values":[8],"x":["KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation"],"y":["GIST with resistance to therapy"]}},"id":"d31551d5-8b44-4f89-bcd9-3f8441f6f4c8","type":"ColumnDataSource"},{"attributes":{"callback":null,"factors":["KIT exon 11 p.550-592 any mutation","KIT exon 8 p.416-422 indel","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT V560del deletion mutation","KIT D820Y missense mutation","KIT amplification copy number gain","KIT D820E missense mutation","KIT del577-578_579 deletion mutation"]},"id":"0831f3cd-3825-4850-8845-6e9fb269c8c2","type":"FactorRange"},{"attributes":{"below":[{"id":"fcae008c-adf9-4780-9229-b320a6446fc8","type":"CategoricalAxis"}],"left":[{"id":"aad59b6a-5efd-4831-848f-9bc237a5d0a3","type":"CategoricalAxis"}],"renderers":[{"id":"0229cf56-f094-48bd-b494-ae7592c790db","type":"GlyphRenderer"},{"id":"e2f5d78f-c34c-4f9b-9437-04535c1ea941","type":"GlyphRenderer"},{"id":"020de3cc-a5ba-411e-a621-ddbfc76a41b4","type":"GlyphRenderer"},{"id":"95c38428-0815-479a-9d2d-1e50e3c4f8af","type":"GlyphRenderer"},{"id":"fcae008c-adf9-4780-9229-b320a6446fc8","type":"CategoricalAxis"},{"id":"aad59b6a-5efd-4831-848f-9bc237a5d0a3","type":"CategoricalAxis"}],"title":{"id":"86df1ed1-dc71-4934-b0b6-b1c4f08c1fdb","type":"Title"},"tool_events":{"id":"2d101e3c-f9af-42c2-975e-e40d54df6a05","type":"ToolEvents"},"toolbar":{"id":"c2c1fc79-f083-49af-9125-fb68df99fe9c","type":"Toolbar"},"toolbar_location":"above","width":1024,"x_mapper_type":"auto","x_range":{"id":"0a4c1cc4-4e8e-4d5f-80ab-096116baacb7","type":"FactorRange"},"y_mapper_type":"auto","y_range":{"id":"3fa3dd4c-35fa-47d4-9801-e08db4a7b326","type":"FactorRange"}},"id":"e4926516-61dc-46a0-9028-408b0af31f76","subtype":"Chart","type":"Plot"},{"attributes":{"below":[{"id":"9ac50b1c-c7fc-4496-a794-2d30c877f952","type":"CategoricalAxis"}],"left":[{"id":"5571b6fa-493d-4faa-bf5b-d26d93762471","type":"CategoricalAxis"}],"renderers":[{"id":"89038575-5642-46c2-8242-478afd78f9fb","type":"GlyphRenderer"},{"id":"9470cc1a-8233-48f3-8d53-87c41126dd7c","type":"GlyphRenderer"},{"id":"d1724d1c-26b8-4bcf-9240-d98adf53a0c5","type":"GlyphRenderer"},{"id":"c7b195b4-a065-433d-9c7a-a9628ba9264d","type":"GlyphRenderer"},{"id":"9ac50b1c-c7fc-4496-a794-2d30c877f952","type":"CategoricalAxis"},{"id":"5571b6fa-493d-4faa-bf5b-d26d93762471","type":"CategoricalAxis"}],"title":{"id":"b306a010-604b-42ab-800c-db7a97187b40","type":"Title"},"tool_events":{"id":"9fc6f758-b7a3-480e-8167-a4096d27db93","type":"ToolEvents"},"toolbar":{"id":"59b637e6-1341-44ff-8cd5-234731558d5d","type":"Toolbar"},"toolbar_location":"above","width":1024,"x_mapper_type":"auto","x_range":{"id":"0831f3cd-3825-4850-8845-6e9fb269c8c2","type":"FactorRange"},"y_mapper_type":"auto","y_range":{"id":"74635a8a-d732-400a-bf0f-f29c2fab49ac","type":"FactorRange"}},"id":"b304ec13-99ef-4b12-8a2f-c6a6bee9d509","subtype":"Chart","type":"Plot"},{"attributes":{"callback":null,"factors":["GIST with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","Melanoma, NOS with response to therapy","Mastocytosis with response to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","Melanoma, NOS with resistance to therapy","GIST with sensitivity to therapy","Melanoma, NOS with no response to therapy"]},"id":"3fa3dd4c-35fa-47d4-9801-e08db4a7b326","type":"FactorRange"},{"attributes":{},"id":"9fc6f758-b7a3-480e-8167-a4096d27db93","type":"ToolEvents"},{"attributes":{},"id":"27b9abd3-ddc2-4c26-bdda-19f85d6e2906","type":"CategoricalTickFormatter"},{"attributes":{"columns":[{"id":"2ff6689d-c21b-4d5a-879b-52e78b4aff87","type":"TableColumn"}],"source":{"id":"b847c6c4-84c0-4475-9bb9-282f0fe22306","type":"ColumnDataSource"},"width":1024},"id":"15bda100-47d2-4ec1-b84c-92b15aeab6ee","type":"DataTable"},{"attributes":{},"id":"a5a7f697-553c-4d08-8270-c76498819dff","type":"CategoricalTicker"},{"attributes":{"children":[{"id":"e4926516-61dc-46a0-9028-408b0af31f76","subtype":"Chart","type":"Plot"},{"id":"5f8c11af-ddb5-4858-a77b-ea729b940d8a","type":"WidgetBox"}]},"id":"43d47202-2a92-4752-876a-13b51c9740e3","type":"Column"},{"attributes":{"children":[{"id":"fdae21f5-55ce-4c36-a117-abcd809c7a0d","type":"DataTable"}],"height":400,"width":1024},"id":"fdad9a6f-b3c9-446b-8149-bb2e5eab8cfd","type":"WidgetBox"},{"attributes":{"editor":{"id":"ca7d5e3b-aa14-4997-b6fd-e18b3a8120c2","type":"StringEditor"},"field":"association_descriptions","formatter":{"id":"2243045b-9101-4363-92aa-8ebb75ae9330","type":"StringFormatter"},"title":"Description"},"id":"6c916f42-9d7c-4b07-af63-0fd55211a266","type":"TableColumn"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(2.5, 4]"],"chart_index":[{"association_count_Sum":"(2.5, 4]"}],"values":[3],"x":["KIT exon 11 p.550-592 any mutation"],"y":["GIST with response to therapy"]}},"id":"49aba474-4a79-4a01-b8f9-43442ea462ae","type":"ColumnDataSource"},{"attributes":{"callback":null,"plot":{"id":"ed96736f-790c-437b-be7f-9bc9e061a02d","subtype":"Chart","type":"Plot"},"tooltips":[["associations","@values"]]},"id":"0b129a11-61d9-442c-96f7-3bceea65c976","type":"HoverTool"},{"attributes":{"data_source":{"id":"92c117b0-9c1f-4e8f-83d3-c09279917cf1","type":"ColumnDataSource"},"glyph":{"id":"13c86fc6-4f9b-44d9-9514-0fabea3b411a","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"020de3cc-a5ba-411e-a621-ddbfc76a41b4","type":"GlyphRenderer"},{"attributes":{"dilate":true,"fill_color":{"value":"#9ecae1"},"height":{"units":"data","value":0.95},"line_color":{"value":"#9ecae1"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"4472018b-b250-4a8b-87b0-f90e26b1dc00","type":"Rect"},{"attributes":{},"id":"a786995f-e1b4-4fd2-9bb7-caa91c3e3420","type":"StringFormatter"},{"attributes":{"callback":null,"factors":["KIT exon 11 p.550-592 any mutation","KIT exon 8 p.416-422 indel","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT V560del deletion mutation","KIT D820Y missense mutation","KIT amplification copy number gain","KIT D820E missense mutation","KIT del577-578_579 deletion mutation"]},"id":"e6f0b92c-e393-44f1-ac62-8f9de7e2ee3d","type":"FactorRange"},{"attributes":{"active_drag":"auto","active_scroll":"auto","active_tap":"auto","tools":[{"id":"0b129a11-61d9-442c-96f7-3bceea65c976","type":"HoverTool"}]},"id":"a0ad3f37-459d-46f1-bc8a-91cea310e5e4","type":"Toolbar"},{"attributes":{"axis_label":"feature","formatter":{"id":"b15fb47f-78a7-45aa-b2b4-f4b39e304f43","type":"CategoricalTickFormatter"},"major_label_orientation":0.7853981633974483,"plot":{"id":"ed96736f-790c-437b-be7f-9bc9e061a02d","subtype":"Chart","type":"Plot"},"ticker":{"id":"9edd6c85-2583-4b21-9306-5906526d532e","type":"CategoricalTicker"}},"id":"4b23ef13-f679-4cea-856c-2f2414f4f778","type":"CategoricalAxis"},{"attributes":{},"id":"f5bac6a2-3e0c-403b-9dd9-48c34960a3f4","type":"CategoricalTickFormatter"},{"attributes":{"dilate":true,"fill_color":{"value":"#6baed6"},"height":{"units":"data","value":0.95},"line_color":{"value":"#6baed6"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"13c86fc6-4f9b-44d9-9514-0fabea3b411a","type":"Rect"},{"attributes":{"dilate":true,"fill_color":{"value":"#08519c"},"height":{"units":"data","value":0.95},"line_color":{"value":"#08519c"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"95af79db-d3d9-4b4f-80ee-34b4b561ba3e","type":"Rect"},{"attributes":{},"id":"ca7d5e3b-aa14-4997-b6fd-e18b3a8120c2","type":"StringEditor"},{"attributes":{"axis_label":"feature","formatter":{"id":"27b9abd3-ddc2-4c26-bdda-19f85d6e2906","type":"CategoricalTickFormatter"},"major_label_orientation":0.7853981633974483,"plot":{"id":"e4926516-61dc-46a0-9028-408b0af31f76","subtype":"Chart","type":"Plot"},"ticker":{"id":"d91ac063-757d-4c88-a983-9a6670818899","type":"CategoricalTicker"}},"id":"fcae008c-adf9-4780-9229-b320a6446fc8","type":"CategoricalAxis"},{"attributes":{},"id":"2243045b-9101-4363-92aa-8ebb75ae9330","type":"StringFormatter"},{"attributes":{},"id":"b15fb47f-78a7-45aa-b2b4-f4b39e304f43","type":"CategoricalTickFormatter"},{"attributes":{},"id":"15ca3379-54f0-4ca3-9cd6-ee55a3396321","type":"CategoricalTicker"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(8.5, 10]"],"chart_index":[{"association_count_Sum":"(8.5, 10]"}],"values":[10],"x":["KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  "],"y":["Melanoma, NOS with response to therapy"]}},"id":"30b0c06a-7cd2-41d0-963d-e99e70072573","type":"ColumnDataSource"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(2.5, 4]"],"chart_index":[{"association_count_Sum":"(2.5, 4]"}],"values":[3],"x":["KIT exon 11 p.550-592 any mutation"],"y":["GIST with response to therapy"]}},"id":"6a386530-8a9b-4f0e-ac2e-91760446b0a0","type":"ColumnDataSource"},{"attributes":{"plot":null,"text":"G2P Associations for KIT"},"id":"2e2ba6e0-7810-40fc-b8a5-1b380315745b","type":"Title"},{"attributes":{},"id":"6bac9814-85c3-47f3-b208-b94d36fc9a34","type":"CategoricalTicker"},{"attributes":{"axis_label":"feature","formatter":{"id":"f5bac6a2-3e0c-403b-9dd9-48c34960a3f4","type":"CategoricalTickFormatter"},"major_label_orientation":0.7853981633974483,"plot":{"id":"b304ec13-99ef-4b12-8a2f-c6a6bee9d509","subtype":"Chart","type":"Plot"},"ticker":{"id":"a5a7f697-553c-4d08-8270-c76498819dff","type":"CategoricalTicker"}},"id":"9ac50b1c-c7fc-4496-a794-2d30c877f952","type":"CategoricalAxis"},{"attributes":{"callback":null,"factors":["GIST with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","Melanoma, NOS with response to therapy","Mastocytosis with response to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","Melanoma, NOS with resistance to therapy","GIST with sensitivity to therapy","Melanoma, NOS with no response to therapy"]},"id":"74635a8a-d732-400a-bf0f-f29c2fab49ac","type":"FactorRange"},{"attributes":{"data_source":{"id":"7a71074e-beb5-4b48-a6bf-d5e46a688538","type":"ColumnDataSource"},"glyph":{"id":"aea13b24-4ef6-46dc-b1ed-ee769aee510d","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"462c3e89-6cb6-4471-93dc-4a4206738801","type":"GlyphRenderer"},{"attributes":{"columns":[{"id":"6c916f42-9d7c-4b07-af63-0fd55211a266","type":"TableColumn"}],"source":{"id":"20ff109b-4416-43a4-9506-c3b71dd31a0b","type":"ColumnDataSource"},"width":1024},"id":"fdae21f5-55ce-4c36-a117-abcd809c7a0d","type":"DataTable"},{"attributes":{"callback":null,"column_names":["association_descriptions","association_count","feature","phenotype"],"data":{"association_count":[1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"association_descriptions":["Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[HSP90 inhibitors] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22898035]","Association: genotype:[KIT exon 8 p.416-422 indel] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy] environment:[imatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/15618474]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/17259998]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16624552|http://www.ncbi.nlm.nih.gov/pubmed/18955458|http://www.ncbi.nlm.nih.gov/pubmed/18955451]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[sunitinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18936790]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/23582185]","Association: genotype:[COSM1321] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy] environment:[dasatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23149070|http://www.ncbi.nlm.nih.gov/pubmed/23149070]","Association: genotype:[KIT D816V missense mutation] phenotype:[Mastocytosis with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18559612|http://www.ncbi.nlm.nih.gov/pubmed/18559612|http://www.ncbi.nlm.nih.gov/pubmed/18559612]","Association: genotype:[KIT exon 14 p.664-714 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT T670I missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/24687822]","Association: genotype:[KIT Y553N missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23375402]","Association: genotype:[KIT H697Y missense mutation] phenotype:[Thymic carcinoma with sensitivity to therapy] environment:[sunitinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19861435]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT V654A missense mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16751810]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/23582185]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18936790]","Association: genotype:[KIT D816V missense mutation] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18986703|http://www.ncbi.nlm.nih.gov/pubmed/18986703|http://www.ncbi.nlm.nih.gov/pubmed/18986703]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22270258]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation] phenotype:[Melanoma, NOS with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21642685|http://www.ncbi.nlm.nih.gov/pubmed/21690468]","Association: genotype:[KIT  exon 13 p.627-664 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT V560del deletion mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/15201427]","Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22270258]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with sensitivity to therapy] environment:[dasatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16397263]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19671763]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[HSP90 inhibitors] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21737509]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21456006|http://www.ncbi.nlm.nih.gov/pubmed/22119758]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[COSM12710] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23775962|http://www.ncbi.nlm.nih.gov/pubmed/23775962]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[sorafenib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT Y553N missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21969494]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[HSP90 inhibitors] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21737509]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/17259998]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22261812]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22068222]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22068222]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19671763]","Association: genotype:[KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/20372153]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT D820E missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19461405]","Association: genotype:[KIT del577-578_579 deletion mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/20970876]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with no response to therapy] environment:[imatinib] evidence:[no_response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23775962]"],"feature":["KIT exon 11 p.550-592 any mutation","KIT exon 8 p.416-422 indel","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT  D816V missense mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 9 p.449-514 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT  wild type no mutation","KIT V560del deletion mutation","KIT exon 11 p.550-592 any mutation","KIT  wild type no mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 11 p.550-592 any mutation","KIT D820Y missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 17 p.788-828 any mutation","KIT amplification copy number gain","KIT Y553N missense mutation","KIT exon 17 p.788-828 any mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT amplification copy number gain","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT exon 17 p.788-828 any mutation","KIT D820E missense mutation","KIT del577-578_579 deletion mutation","KIT amplification copy number gain"],"phenotype":["GIST with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with resistance to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","Melanoma, NOS with response to therapy","GIST with resistance to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","Mastocytosis with response to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","Melanoma, NOS with response to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with response to therapy","Thymic carcinoma with response to therapy","GIST with response to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","GIST with sensitivity to therapy","GIST with response to therapy","GIST with resistance to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","GIST with resistance to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Thymic carcinoma with response to therapy","GIST with sensitivity to therapy","GIST with resistance to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","GIST with decreased sensitivity to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with response to therapy","Melanoma, NOS with no response to therapy"]}},"id":"b847c6c4-84c0-4475-9bb9-282f0fe22306","type":"ColumnDataSource"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]"],"chart_index":[{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"}],"values":[1,1,2,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1],"x":["KIT exon 8 p.416-422 indel","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT  D816V missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT  wild type no mutation","KIT V560del deletion mutation","KIT  wild type no mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT D820Y missense mutation","KIT exon 17 p.788-828 any mutation","KIT amplification copy number gain","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT D820E missense mutation","KIT del577-578_579 deletion mutation","KIT amplification copy number gain"],"y":["ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","Mastocytosis with response to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","GIST with response to therapy","Melanoma, NOS with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with response to therapy","Thymic carcinoma with response to therapy","GIST with sensitivity to therapy","GIST with sensitivity to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with response to therapy","Melanoma, NOS with no response to therapy"]}},"id":"528480e9-9b7b-4746-a1e3-cf85bc04b4f4","type":"ColumnDataSource"},{"attributes":{},"id":"d91ac063-757d-4c88-a983-9a6670818899","type":"CategoricalTicker"},{"attributes":{"active_drag":"auto","active_scroll":"auto","active_tap":"auto","tools":[{"id":"58b9699e-4f4b-47a7-9689-380bf61ea448","type":"HoverTool"}]},"id":"59b637e6-1341-44ff-8cd5-234731558d5d","type":"Toolbar"},{"attributes":{"callback":null,"column_names":["association_descriptions","association_count","feature","phenotype"],"data":{"association_count":[1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"association_descriptions":["Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[HSP90 inhibitors] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22898035]","Association: genotype:[KIT exon 8 p.416-422 indel] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy] environment:[imatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/15618474]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/17259998]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16624552|http://www.ncbi.nlm.nih.gov/pubmed/18955458|http://www.ncbi.nlm.nih.gov/pubmed/18955451]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[sunitinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18936790]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/23582185]","Association: genotype:[COSM1321] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy] environment:[dasatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23149070|http://www.ncbi.nlm.nih.gov/pubmed/23149070]","Association: genotype:[KIT D816V missense mutation] phenotype:[Mastocytosis with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18559612|http://www.ncbi.nlm.nih.gov/pubmed/18559612|http://www.ncbi.nlm.nih.gov/pubmed/18559612]","Association: genotype:[KIT exon 14 p.664-714 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT T670I missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/24687822]","Association: genotype:[KIT Y553N missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23375402]","Association: genotype:[KIT H697Y missense mutation] phenotype:[Thymic carcinoma with sensitivity to therapy] environment:[sunitinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19861435]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT V654A missense mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16751810]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/23582185]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18936790]","Association: genotype:[KIT D816V missense mutation] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18986703|http://www.ncbi.nlm.nih.gov/pubmed/18986703|http://www.ncbi.nlm.nih.gov/pubmed/18986703]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22270258]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation] phenotype:[Melanoma, NOS with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21642685|http://www.ncbi.nlm.nih.gov/pubmed/21690468]","Association: genotype:[KIT  exon 13 p.627-664 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT V560del deletion mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/15201427]","Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22270258]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with sensitivity to therapy] environment:[dasatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16397263]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19671763]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[HSP90 inhibitors] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21737509]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21456006|http://www.ncbi.nlm.nih.gov/pubmed/22119758]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[COSM12710] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23775962|http://www.ncbi.nlm.nih.gov/pubmed/23775962]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[sorafenib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT Y553N missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21969494]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[HSP90 inhibitors] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21737509]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/17259998]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22261812]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22068222]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22068222]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19671763]","Association: genotype:[KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/20372153]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT D820E missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19461405]","Association: genotype:[KIT del577-578_579 deletion mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/20970876]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with no response to therapy] environment:[imatinib] evidence:[no_response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23775962]"],"feature":["KIT exon 11 p.550-592 any mutation","KIT exon 8 p.416-422 indel","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT  D816V missense mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 9 p.449-514 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT  wild type no mutation","KIT V560del deletion mutation","KIT exon 11 p.550-592 any mutation","KIT  wild type no mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 11 p.550-592 any mutation","KIT D820Y missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 17 p.788-828 any mutation","KIT amplification copy number gain","KIT Y553N missense mutation","KIT exon 17 p.788-828 any mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT amplification copy number gain","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT exon 17 p.788-828 any mutation","KIT D820E missense mutation","KIT del577-578_579 deletion mutation","KIT amplification copy number gain"],"phenotype":["GIST with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with resistance to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","Melanoma, NOS with response to therapy","GIST with resistance to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","Mastocytosis with response to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","Melanoma, NOS with response to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with response to therapy","Thymic carcinoma with response to therapy","GIST with response to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","GIST with sensitivity to therapy","GIST with response to therapy","GIST with resistance to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","GIST with resistance to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Thymic carcinoma with response to therapy","GIST with sensitivity to therapy","GIST with resistance to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","GIST with decreased sensitivity to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with response to therapy","Melanoma, NOS with no response to therapy"]}},"id":"c23780cd-1fc4-403a-9930-bf03aa428cc1","type":"ColumnDataSource"},{"attributes":{"dilate":true,"fill_color":{"value":"#6baed6"},"height":{"units":"data","value":0.95},"line_color":{"value":"#6baed6"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"ff0a6ba1-774d-4126-a732-7201bbbb27a9","type":"Rect"},{"attributes":{"active_drag":"auto","active_scroll":"auto","active_tap":"auto","tools":[{"id":"8e780433-2985-460c-8713-749ff8e085fc","type":"HoverTool"}]},"id":"c2c1fc79-f083-49af-9125-fb68df99fe9c","type":"Toolbar"},{"attributes":{},"id":"aa31737d-002c-47d7-8794-b77075f02aca","type":"ToolEvents"},{"attributes":{"callback":null,"factors":["KIT exon 11 p.550-592 any mutation","KIT exon 8 p.416-422 indel","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT V560del deletion mutation","KIT D820Y missense mutation","KIT amplification copy number gain","KIT D820E missense mutation","KIT del577-578_579 deletion mutation"]},"id":"0a4c1cc4-4e8e-4d5f-80ab-096116baacb7","type":"FactorRange"},{"attributes":{},"id":"938484eb-2a62-451d-869b-deaf08e5352f","type":"CategoricalTickFormatter"},{"attributes":{"callback":null,"column_names":["association_descriptions","association_count","feature","phenotype"],"data":{"association_count":[1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"association_descriptions":["Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[HSP90 inhibitors] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22898035]","Association: genotype:[KIT exon 8 p.416-422 indel] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy] environment:[imatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/15618474]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/17259998]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16624552|http://www.ncbi.nlm.nih.gov/pubmed/18955458|http://www.ncbi.nlm.nih.gov/pubmed/18955451]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[sunitinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18936790]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/23582185]","Association: genotype:[COSM1321] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy] environment:[dasatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23149070|http://www.ncbi.nlm.nih.gov/pubmed/23149070]","Association: genotype:[KIT D816V missense mutation] phenotype:[Mastocytosis with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18559612|http://www.ncbi.nlm.nih.gov/pubmed/18559612|http://www.ncbi.nlm.nih.gov/pubmed/18559612]","Association: genotype:[KIT exon 14 p.664-714 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT T670I missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/24687822]","Association: genotype:[KIT Y553N missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23375402]","Association: genotype:[KIT H697Y missense mutation] phenotype:[Thymic carcinoma with sensitivity to therapy] environment:[sunitinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19861435]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT V654A missense mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16751810]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/23582185]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18936790]","Association: genotype:[KIT D816V missense mutation] phenotype:[ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18986703|http://www.ncbi.nlm.nih.gov/pubmed/18986703|http://www.ncbi.nlm.nih.gov/pubmed/18986703]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22270258]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation] phenotype:[Melanoma, NOS with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21642685|http://www.ncbi.nlm.nih.gov/pubmed/21690468]","Association: genotype:[KIT  exon 13 p.627-664 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[KIT V560del deletion mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/15201427]","Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22270258]","Association: genotype:[KIT  wild type no mutation] phenotype:[GIST with sensitivity to therapy] environment:[dasatinib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/16397263]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19671763]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/22261812|http://www.ncbi.nlm.nih.gov/pubmed/18421059|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT exon 9 p.449-514 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[HSP90 inhibitors] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21737509]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21456006|http://www.ncbi.nlm.nih.gov/pubmed/22119758]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT exon 11 p.550-592 any mutation] phenotype:[GIST with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/18955458]","Association: genotype:[COSM12710] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23775962|http://www.ncbi.nlm.nih.gov/pubmed/23775962]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/17259998|http://www.ncbi.nlm.nih.gov/pubmed/21689725]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[sorafenib] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21690468|http://www.ncbi.nlm.nih.gov/pubmed/21642685]","Association: genotype:[KIT Y553N missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[imatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21969494]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with sensitivity to therapy] environment:[HSP90 inhibitors] evidence:[sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/21737509]","Association: genotype:[KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation] phenotype:[GIST with resistance to therapy] environment:[imatinib] evidence:[resistance] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23582185|http://www.ncbi.nlm.nih.gov/pubmed/21689725|http://www.ncbi.nlm.nih.gov/pubmed/17259998]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with response to therapy] environment:[sunitinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22261812]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22068222]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[nilotinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/22068222]","Association: genotype:[KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ] phenotype:[Melanoma, NOS with response to therapy] environment:[dasatinib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19671763]","Association: genotype:[KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation] phenotype:[Melanoma, NOS with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/20372153]","Association: genotype:[KIT exon 17 p.788-828 any mutation] phenotype:[GIST with decreased sensitivity to therapy] environment:[imatinib] evidence:[decreased_sensitivity] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23840364]","Association: genotype:[KIT D820E missense mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/19461405]","Association: genotype:[KIT del577-578_579 deletion mutation] phenotype:[Thymic carcinoma with response to therapy] environment:[sorafenib] evidence:[response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/20970876]","Association: genotype:[KIT amplification copy number gain] phenotype:[Melanoma, NOS with no response to therapy] environment:[imatinib] evidence:[no_response] publications:[http://www.ncbi.nlm.nih.gov/pubmed/23775962]"],"feature":["KIT exon 11 p.550-592 any mutation","KIT exon 8 p.416-422 indel","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT  D816V missense mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 9 p.449-514 any mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT  wild type no mutation","KIT V560del deletion mutation","KIT exon 11 p.550-592 any mutation","KIT  wild type no mutation","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 11 p.550-592 any mutation","KIT D820Y missense mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT exon 17 p.788-828 any mutation","KIT amplification copy number gain","KIT Y553N missense mutation","KIT exon 17 p.788-828 any mutation","KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation","KIT amplification copy number gain","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT exon 17 p.788-828 any mutation","KIT D820E missense mutation","KIT del577-578_579 deletion mutation","KIT amplification copy number gain"],"phenotype":["GIST with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with resistance to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","Melanoma, NOS with response to therapy","GIST with resistance to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","Mastocytosis with response to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","GIST with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","Melanoma, NOS with response to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with response to therapy","Thymic carcinoma with response to therapy","GIST with response to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","GIST with sensitivity to therapy","GIST with response to therapy","GIST with resistance to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","GIST with resistance to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Thymic carcinoma with response to therapy","GIST with sensitivity to therapy","GIST with resistance to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","GIST with decreased sensitivity to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with response to therapy","Melanoma, NOS with no response to therapy"]}},"id":"20ff109b-4416-43a4-9506-c3b71dd31a0b","type":"ColumnDataSource"},{"attributes":{},"id":"fd52a9d8-8199-4f89-b5da-9698e23f70c0","type":"StringEditor"},{"attributes":{"dilate":true,"fill_color":{"value":"#3182bd"},"height":{"units":"data","value":0.95},"line_color":{"value":"#3182bd"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"a4f3e6c8-cd88-4936-98d0-2ecd7d0b8d5f","type":"Rect"},{"attributes":{"children":[{"id":"15bda100-47d2-4ec1-b84c-92b15aeab6ee","type":"DataTable"}],"height":400,"width":1024},"id":"8bf9dd7b-50a9-40dc-b1b1-5bc5b4b81cf2","type":"WidgetBox"},{"attributes":{},"id":"6982d493-7f65-44a4-94e8-0977f5c4e695","type":"CategoricalTickFormatter"},{"attributes":{"editor":{"id":"7bdb652c-6b2e-4507-9f60-80caad9875f4","type":"StringEditor"},"field":"association_descriptions","formatter":{"id":"9ab2a56c-7632-4de2-84ef-509ce8ea9c85","type":"StringFormatter"},"title":"Description"},"id":"bcf2e0e2-a4f9-4bb4-ac97-c64feca9091b","type":"TableColumn"},{"attributes":{"dilate":true,"fill_color":{"value":"#08519c"},"height":{"units":"data","value":0.95},"line_color":{"value":"#08519c"},"width":{"units":"data","value":0.95},"x":{"field":"x"},"y":{"field":"y"}},"id":"aea13b24-4ef6-46dc-b1ed-ee769aee510d","type":"Rect"},{"attributes":{"data_source":{"id":"49aba474-4a79-4a01-b8f9-43442ea462ae","type":"ColumnDataSource"},"glyph":{"id":"ff0a6ba1-774d-4126-a732-7201bbbb27a9","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"d1724d1c-26b8-4bcf-9240-d98adf53a0c5","type":"GlyphRenderer"},{"attributes":{},"id":"7bdb652c-6b2e-4507-9f60-80caad9875f4","type":"StringEditor"},{"attributes":{"data_source":{"id":"4ffb8a64-8faf-4270-ae11-655871819d22","type":"ColumnDataSource"},"glyph":{"id":"c0be3707-b3a4-4dc0-9f1a-5eb3fa9870a8","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"d272a6ed-79f6-4ba2-85dc-3d6b15cad1e6","type":"GlyphRenderer"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(8.5, 10]"],"chart_index":[{"association_count_Sum":"(8.5, 10]"}],"values":[10],"x":["KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  "],"y":["Melanoma, NOS with response to therapy"]}},"id":"7a71074e-beb5-4b48-a6bf-d5e46a688538","type":"ColumnDataSource"},{"attributes":{},"id":"7ae607e2-f81d-4771-b5ba-667b12dcb051","type":"CategoricalTicker"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(8.5, 10]"],"chart_index":[{"association_count_Sum":"(8.5, 10]"}],"values":[10],"x":["KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  "],"y":["Melanoma, NOS with response to therapy"]}},"id":"94bd7f14-7783-4246-9e4f-b7e39138ce1d","type":"ColumnDataSource"},{"attributes":{"editor":{"id":"fd52a9d8-8199-4f89-b5da-9698e23f70c0","type":"StringEditor"},"field":"association_descriptions","formatter":{"id":"a786995f-e1b4-4fd2-9bb7-caa91c3e3420","type":"StringFormatter"},"title":"Description"},"id":"2ff6689d-c21b-4d5a-879b-52e78b4aff87","type":"TableColumn"},{"attributes":{"data_source":{"id":"94bd7f14-7783-4246-9e4f-b7e39138ce1d","type":"ColumnDataSource"},"glyph":{"id":"ae89abe6-5cb5-4013-a55a-f654895f24ea","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"0229cf56-f094-48bd-b494-ae7592c790db","type":"GlyphRenderer"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["(7, 8.5]"],"chart_index":[{"association_count_Sum":"(7, 8.5]"}],"values":[8],"x":["KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation"],"y":["GIST with resistance to therapy"]}},"id":"3c43bcf5-2bac-4072-b7d6-a5f81a9089d5","type":"ColumnDataSource"},{"attributes":{"callback":null,"column_names":["y","x","values"],"data":{"association_count_Sum":["[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]","[1, 2.5]"],"chart_index":[{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"},{"association_count_Sum":"[1, 2.5]"}],"values":[1,1,2,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1],"x":["KIT exon 8 p.416-422 indel","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT N822K missense mutation","KIT  D816V missense mutation","KIT exon 14 p.664-714 any mutation","KIT T670I missense mutation","KIT Y553N missense mutation","KIT H697Y missense mutation","KIT  wild type no mutation","KIT V654A missense mutation","KIT  D816V missense mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT  exon 13 p.627-664 any mutation","KIT  wild type no mutation","KIT V560del deletion mutation","KIT  wild type no mutation","KIT exon 9 p.449-514 any mutation","KIT exon 17 p.788-828 any mutation","KIT D820Y missense mutation","KIT exon 17 p.788-828 any mutation","KIT amplification copy number gain","KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation","KIT D820E missense mutation","KIT del577-578_579 deletion mutation","KIT amplification copy number gain"],"y":["ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with sensitivity to therapy","Mastocytosis with response to therapy","GIST with decreased sensitivity to therapy","GIST with resistance to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with sensitivity to therapy","GIST with decreased sensitivity to therapy","GIST with decreased sensitivity to therapy","ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS with response to therapy","GIST with response to therapy","Melanoma, NOS with resistance to therapy","GIST with decreased sensitivity to therapy","GIST with response to therapy","Thymic carcinoma with response to therapy","GIST with sensitivity to therapy","GIST with sensitivity to therapy","GIST with response to therapy","Melanoma, NOS with response to therapy","GIST with sensitivity to therapy","Melanoma, NOS with response to therapy","Melanoma, NOS with response to therapy","Thymic carcinoma with response to therapy","Thymic carcinoma with response to therapy","Melanoma, NOS with no response to therapy"]}},"id":"5c592772-76e2-4f36-8142-700dfb4ef188","type":"ColumnDataSource"},{"attributes":{"data_source":{"id":"6a386530-8a9b-4f0e-ac2e-91760446b0a0","type":"ColumnDataSource"},"glyph":{"id":"9c6efd8f-e7de-4c3b-8688-a1efa4c0060b","type":"Rect"},"hover_glyph":null,"nonselection_glyph":null,"selection_glyph":null},"id":"597a4e97-4761-474a-ab93-4e943d435eff","type":"GlyphRenderer"},{"attributes":{},"id":"9edd6c85-2583-4b21-9306-5906526d532e","type":"CategoricalTicker"}],"root_ids":["5408e6a3-f8ec-401d-9854-f663f63c0b81","28325ef4-0d60-4aa6-b910-4960dc5a3d1c","43d47202-2a92-4752-876a-13b51c9740e3"]},"title":"Bokeh Application","version":"0.12.3"}};
                var render_items = [{"docid":"160801ec-0357-4b8b-9c1c-de4999d90814","elementid":"f040c4f1-247f-4c3e-b0c0-eaacde681cf6","modelid":"43d47202-2a92-4752-876a-13b51c9740e3"}];
                
                Bokeh.embed.embed_items(docs_json, render_items);
            });
        });
        </script>
    </body>
</html>